An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
← catalyst calendarSponsored by MoonLake Immunotherapeutics AG (industry) · MLTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Other
Enrollment
120actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-05 | actual | When the study began enrolling |
| Primary completion | 2025-11-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-01 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relative Bioequivalence
Interventions
- Drug: Sonelokimab
- Drug: Sonelokimab
Primary outcomes
what the primary-completion date above is the date OFComparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimab
measured 64 days
Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimab
measured 64 days
Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimab
measured 64 days
Permalink · MLTX's whole pipeline · Catalyst calendar · Every registered study · What changed